OncoMed Pharmaceuticals, Inc. OMED, +6.44% a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that John Lewicki, Ph.D., President and Chief Executive Officer of OncoMed, will provide a corporate update at two upcoming investor conferences. 

• Wells Fargo Securities 2018 Healthcare Conference in Boston, MA on September 5, 2018 at 9:40 am Eastern Time
• 20 [th] Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC in New York, NY on September 6, 2018 at 4:40 pm Eastern Time

​To access the live webcasts and subsequent archived recordings of these and other company presentations, please visit OncoMed's website at www.oncomed.com/invest/events.cfm. A replay of each presentation will be available for 30 days following the date of the event.

Read More: https://www.marketwatch.com/press-release/oncomed-to-present-at-two-upcoming-investor-conferences-in-september-2018-08-29

SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, today announced that it raised $132 million in a Series D equity financing. The round was led by new investor Mubadala Investment Company, Abu Dhabi’s leading investment company, active in numerous sectors and more than 30 countries around the world. Existing investors Baxter Ventures, the venture capital arm of Baxter International, Fidelity Management and Research Company, Partner Fund Management LP, Perceptive Advisors, funds advised by T. Rowe Price Associates Inc., and Warburg Pincus also participated in the equity round.

The company will use the proceeds from the financing to increase production capabilities and accelerate commercial expansion of its Tablo®Hemodialysis System in acute and chronic care markets in the United States. Designed to reduce the cost and complexity of dialysis, Tablo expands how, when, and where dialysis can be provided.

Read More: https://www.businesswire.com/news/home/20180828005589/en/Outset-Medical-Closes-132-Million-Financing-Accelerate

MORGANTOWN, W.Va. – Surgeons at the WVU Heart and Vascular Institute are now offering a new minimally invasive treatment for patients with carotid artery disease.

The carotid arteries are the two large blood vessels in the neck that supply the brain and head with blood. Carotid artery disease occurs when the arteries become narrow or blocked as the result of a buildup of fatty plaque. This can cause small clots to form, and those clots can cause a stroke.

Currently, the most common treatments for severe carotid artery disease are carotid endarterectomy, an open surgical procedure, and transfemoral carotid angioplasty and stenting, a minimally invasive option for patients at high risk for stroke and other complications.

Surgeons at the WVU Heart and Vascular Institute are now performing transcarotid artery revascularization (TCAR) using the ENROUTE® Transcarotid Neuroprotection System, which is designed to reduce the risk of stroke while inserting the ENROUTE® Transcarotid Stent. 

Read More: https://wvumedicine.org/news/article/wvu-heart-and-vascular-institute-offering-new-procedure-for-carotid-artery-disease/

Since its introduction in the 1950s, carotid endarterectomy (CEA) has been considered the gold standard treatment option for carotid revascularization. However, in patients with high-risk anatomic and/or physiologic characteristics, CEA is associated with higher rates of adverse outcomes.1 Transfemoral carotid angioplasty and stenting (TF-CAS) was introduced over 2 decades ago as a potential alternative. However, its effectiveness compared to CEA remains unclear, and full adoption of TF-CAS has been hindered by a higher rate of periprocedural stroke.2

Transcarotid artery revascularization (TCAR) was first introduced in the United States in 2012. TCAR is a surgically inspired procedure based upon concepts developed by vascular surgeons Enrique Criado, MD, and David Chang, MD. The technique combines direct carotid artery access and robust reversal of flow during transcarotid stent placement to provide CEA-like neuroprotection in a less-invasive approach.3

Read More: https://evtoday.com/2018/08/supplement/tcar-transcarotid-artery-revascularization-the-next-step-in-the-evolution-of-carotid-revascularization/